Nusinersen (Spinraza®), the first drug approved for the treatment of SMA, is an antisense oligonucleotide, which increases the amount of functional SMN protein in the central nervous system by alternative splicing of the SMN2 gene [10]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.